Skip to main content

Table 3 Multivariate analysis of factors associated with OS in patients with CN-AML

From: TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia

 

B

SE

Wald

P

Exp (B)

95% CI

Age

0.039

0.017

5.017

0.025

1.040

1.005 to 1.076

WBC

−0.004

0.004

1.250

0.264

0.996

0.989 to 1.003

Hb

0.008

0.009

0.769

0.381

1.008

0.990 to 1.027

PLT

0.003

0.003

1.242

0.265

1.003

0.997 to 1.009

PB blasts

−0.006

0.011

0.326

0.568

0.994

0.972 to 1.016

BM blasts

0.029

0.015

3.584

0.058

1.030

0.999 to 1.061

Allo-SCT

0.323

0.614

0.277

0.599

0.724

0.217 to 2.411

NPM1

−0.197

0.432

0.209

0.648

0.821

0.352 to 1.914

CEBPA

−0.880

0.543

2.620

0.106

0.415

0.143 to 1.204

FLT3-ITD

−0.980

0.804

1.484

0.223

0.375

0.078 to 1.816

C-KIT

−12.589

644.378

0.000

0.984

0.000

 

TIGAR

0.868

0.381

5.200

0.023

2.383

1.130 to 5.025

Chemotherapy

0.587

0.333

3.114

0.078

1.799

0.937 to 3.455

  1. Allo-SCT allogeneic hematopoietic stem cell transplantation, BM bone marrow, Hb hemoglobin, PB peripheral blood, PLT platelets, WBC white blood cells
  2. The italicized number represented P < 0.05